

FDA Perspective on Latest Regulatory Initiatives and Pathways

Hiren Mistry

Office of Cardiovascular Devices

CDRH, FDA

- I have no disclosures.

Acknowledgements

- Misti Malone, PhD
- Kenneth Cavanaugh, PhD
- Andrew Farb, MD

Global Innovation

As devices evolve through innovation so to must the regulatory bodies

- Create pathways for innovative devices
- Foster novel areas
- Incorporate patients perspectives
- Build platforms to better evaluate devices across TPLC
- Build global networks



New-ish Pathways

Breakthrough Device Pathway

Intended for medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

Safer Technologies Program (STeP)

Intended for medical devices and device-led combination products that are reasonably expected to significantly improve the safety of currently available treatments or diagnostics that target an underlying disease or condition associated with morbidities and mortalities less serious than those eligible for the Breakthrough Devices Program

Safety and Performance Based Pathway


For particular devices, FDA develops guidance establishing device-specific performance criteria based on data from existing devices, literature, etc.

FOSTERING NOVEL AREAS

EXAMPLE - DIGITAL HEALTH

Fostering Digital Health

The convergence of connectivity, data and computing power for healthcare and related uses across the life of an individual or a patient.



Leveraging computing power, sensors, connectivity and software

INCORPORATING PATIENTS PERSPECTIVES


Patients are at the Heart of All We Do




CDRH Vision:

Patients in the U.S. have access to high-quality, safe, and effective medical devices of public health importance, first in the world.

Patient Input Useful Across TPLC



**BUILD PLATFORMS TO BETTER EVALUATE
DEVICES ACROSS TPLC
EXAMPLE - RWE**




RWE Successes




Clinical
Specialty

Cardiovascular
Diagnostics
General Hospital
Neurological
Ophthalmic
Orthopedics
Surgical




Submission
Type

510(k)
De Novo
PMA
HDE




Data Source

Medical Records
or Charts
Claims
Registry
S-I Studies
Literature



Purpose

New Marketing
Submissions
Indication Expansion
Postmarket Study
Signal Detection



Role

Primary
Supplementary
Partnering
Find patients

BUILD GLOBAL NETWORKS



IMDRF International Medical Device Regulators Forum



Australia



USA



Brazil

South Korea



Canada

Singapore



China

Russia



Europe



Japan

- Voluntary effort involving medical device regulators from around the world to harmonize various regulatory requirements across their jurisdictions
- Proposed IMDRF documents incorporate public comments prior to finalization and adoption
- Net result: increased global regulatory cooperation and review process efficiency

IMDRF Model for Future Single-Review Program




Figure 1 from IMDRF/GRRP WG/N61



FDA

U.S. FOOD & DRUG
ADMINISTRATION